Analyzing Pernix Therapeutics (PTX) and BioLife Solutions (BLFS)

Pernix Therapeutics (NASDAQ: PTX) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Pernix Therapeutics and BioLife Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pernix Therapeutics -97.10% N/A -37.13%
BioLife Solutions -52.10% -49.92% -29.47%

Analyst Ratings

This is a summary of recent recommendations for Pernix Therapeutics and BioLife Solutions, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pernix Therapeutics 0 0 0 0 N/A
BioLife Solutions 0 0 2 0 3.00

BioLife Solutions has a consensus price target of $6.50, suggesting a potential upside of 17.33%. Given BioLife Solutions’ higher probable upside, analysts plainly believe BioLife Solutions is more favorable than Pernix Therapeutics.

Earnings & Valuation

This table compares Pernix Therapeutics and BioLife Solutions’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pernix Therapeutics $140.86 million 0.23 -$169.59 million ($14.78) -0.19
BioLife Solutions $8.23 million 9.17 -$6.87 million ($0.42) -13.19

BioLife Solutions has lower revenue, but higher earnings than Pernix Therapeutics. BioLife Solutions is trading at a lower price-to-earnings ratio than Pernix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

17.4% of Pernix Therapeutics shares are held by institutional investors. Comparatively, 9.4% of BioLife Solutions shares are held by institutional investors. 1.4% of Pernix Therapeutics shares are held by insiders. Comparatively, 36.8% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Pernix Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.

Summary

BioLife Solutions beats Pernix Therapeutics on 8 of the 12 factors compared between the two stocks.

About Pernix Therapeutics

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

About BioLife Solutions

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

Receive News & Ratings for Pernix Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply